Health Care Archives - Page 472 of 478

1 minute read

Humanigen’s Lenzilumab Disappoints In NIH-Backed COVID-19 Study

July 13, 7:39 AM

Humanigen Inc (NASDAQ: HGEN) has been informed of preliminary topline results from the ACTIV-5/BET-B trial evaluating lenzilumab plus remdesivir versus placebo plus remdesivir in hospitalized COVID-19 patients.

HGEN

1 minute read

Endo Weighing Chapter 11 Filing Before Junior Creditors, Opioid Settlements: Report

By Vandana Singh

July 13, 6:34 AM

Endo International Plc (NASDAQ:ENDP) is considering bankruptcy filing to restructure its more than $8 billion of debt and several…

ENDP

1 minute read

Vaxcyte Concludes Enrolment In Mid-Stage Pneumococcal Disease Study

By Ragothaman Srinivasan

July 12, 5:01 PM

Vaxcyte (NASDAQ: PCVX) completed patient enrollment in the Phase 2 portion of the ongoing Phase 1/2 proof-of-concept study evaluating VAX-24 in healthy adults 50 to 64 years of age.

PCVX

1 minute read

Avidity Biosciences Or Dyne Therapeutics – Read On Raymond James’ Rating Skew

By Vandana Singh

July 12, 2:54 PM

Raymond James initiated coverage on Avidity Biosciences Inc (NASDAQ:RNA) with a Strong Buy rating and $29 price target (68% upside) and Dyne Therapeutics Inc (NASDAQ:DYN)…

DYN

1 minute read

HC Wainwright Sees Agile Therapeutics’ Twirla Tailwinds Post Roe-Wade Ruling

By Vandana Singh

July 12, 2:33 PM

Agile Therapeutics Inc's (NASDAQ: AGRX) Twirla, the only low-dose transdermal hormonal contraceptive, should have tailwinds protected after the Supreme Court overturned Roe vs. Wade ruling that legalized abortion nationwide.

AGRX

1 minute read

Hoth Therapeutics Shares Surge On Encouraging Preclinical Data From Alzheimer’s Program

By Vandana Singh

July 12, 2:24 PM

Hoth Therapeutics Inc (NASDAQ:HOTH) has announced proof-of-concept data generated using cognitive and behavioral assessments in an Alzheimer’s disease mouse model. HT-ALZ…

HOTH

1 minute read

Analysts Cuts Price Target On MacroGenics – Read Why

By Vandana Singh

July 12, 1:56 PM

BMO Capital Markets downgraded MacroGenics Inc (NASDAQ:MGNX) to Market Perform following the discontinuation of enoblituzumab (B7H3 antibody) for head and neck cancers. The…

MGNX

1 minute read

Despite Durability Questions, BMO Upgraded This Natural-Killer Cell Therapy Oncology Stock

By Vandana Singh

July 12, 1:44 PM

BMO Capital Market upgraded Fate Therapeutics Inc (NASDAQ:FATE) to Outperform from Market Perform. The analyst believes Fate’s iPSC platform is uniquely positioned…

FATE

1 minute read

Traders Bet Moderna Could Rise By This Much

By Priya Nigam

July 12, 12:26 PM

Moderna Inc. (NASDAQ: MRNA) announced Monday, July 11, that its omicron booster candidate has showed a stronger response against subvariants than its original shot.

MRNA

1 minute read

Abbott’s Deep Brain Stimulation Receives FDA’s Breakthrough Device Tag To Manage Depression

By Vandana Singh

July 12, 10:20 AM

The FDA has granted Breakthrough Device Designation to Abbott Laboratories (NYSE:ABT) deep brain stimulation (DBS) system in treatment-resistant depression (TRD), a form…

ABT